For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with ...

During a live event, Xiuning Le, MD, PhD, discussed clinical trials of supportive care for infusion reaction and skin rash ...

Dr. Suresh Ramalingam discussed how the LAURA findings support the role of Tagrisso as a backbone therapy across multiple ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...

UB medicinal chemist David Heppner has received the 2025 Philip S. Portoghese Lectureship Award from the American Chemical ...

Janssen-Cilag International NV, a Johnson & Johnson company, has submitted an application to the European Medicines Agency ...

Further research is welcome, pending which, current preference remains with use of single-agent osimertinib with or without chemotherapy or with combination bispecific antibody and lazertinib TKI ...

Lazertinib is also under evaluation for the same indication, likely to be used in combination with amivantamab, offering a more comprehensive approach to addressing molecular alterations.